Clinical Trials Logo

Ocular Surface Disease clinical trials

View clinical trials related to Ocular Surface Disease.

Filter by:

NCT ID: NCT06427629 Recruiting - Clinical trials for Ocular Surface Disease

Investigator-initiated Clinical Trial to Observe Conjunctival Goblet Cell Using an Anterior Segment Imaging Device

Start date: June 12, 2024
Phase: N/A
Study type: Interventional

Conjunctival goblet cells secrete mucin, vital for tear film stability. Dysfunction can cause tear film issues and lead to diseases like dry eye. Imaging these cells is crucial for diagnosis and treatment. 0.5% moxifloxacin eye drops, an FDA-approved antibiotic, are used to treat bacterial eye infections and prevent infections before surgeries. The investigators developed a non-invasive imaging method for goblet cells, validated in animals, and now plan to test it in humans for diagnosing and treating ocular surface diseases.

NCT ID: NCT06404541 Active, not recruiting - Dry Eye Syndromes Clinical Trials

A Comparative Study Between Preservative With Benzalkonium Chloride vs Preservative Free Eye Drops on the Ocular Surface

Start date: January 10, 2024
Phase: Phase 4
Study type: Interventional

study the effect of different concentrations of benzalkonium chloride on the ocular surface of non-dry-eyed patients post cataract surgery.

NCT ID: NCT06375343 Not yet recruiting - Dry Eye Disease Clinical Trials

Study to Evaluating PRO-240 Ophthalmic Solution Compared to Optive®

Start date: October 30, 2024
Phase: Phase 1
Study type: Interventional

This is a phase I clinical study to evaluating safety and tolerability of PRO-240 ophthalmic solution through the incidence of unexpected adverse events, as well as through changes in Best Corrected Visual Acuity (BCVA), and the incidence of stinging after its administration, compared to Optive®.

NCT ID: NCT06370585 Not yet recruiting - Dry Eye Disease Clinical Trials

Clinical Study to Evaluate the Safety and Tolerability of PRO-229 Ophthalmic Solution Compared to Lagricel® Ofteno PF

Start date: May 30, 2024
Phase: Phase 1
Study type: Interventional

This is a phase I study evaluating safety and tolerability of PRO-229 ophthalmic solution through he incidence of unexpected adverse events, changes in Best Corrected Visual Acuity (BCVA), incidence of chemosis, and changes in ocular surface staining using the Sjögren's International Collaborative Clinical Alliance (SICCA) Ocular Staining Score (OSS) scale compared to Lagricel® Ofteno PF in clinically healthy subjects.

NCT ID: NCT06355128 Active, not recruiting - COVID-19 Clinical Trials

A Cross-sectional Study of Ocular Manifestations During the Covid-19 Pandemic in Hubei Province

Start date: January 1, 2024
Phase:
Study type: Observational [Patient Registry]

To investigate the clinical features of ocular manifestations during the novel coronavirus pneumonia pandemic in Hubei at the end of 2022

NCT ID: NCT06298890 Recruiting - Cataract Clinical Trials

The Pattern of Dry Eye Disease After Cataract Surgery

Start date: March 2024
Phase:
Study type: Observational

This study is designed to explore dry eye disease (DED) pattern: ocular surface, corneal morphological changes, patients' subjective assessment of DED and their correlations with ocular surface inflammation, pain biomarkers after cataract surgery according to ocular surface lubrication with artificial tears during long-term follow-up.

NCT ID: NCT06256770 Recruiting - Clinical trials for Ocular Surface Disease

Evaluation of the Safety and Efficacy of Rigid Breathable Scleral Contact Lenses for the Correction of Ametropia

Start date: November 1, 2022
Phase:
Study type: Observational

To evaluate the short-term efficacy and safety of scleral contact lens in the clinical treatment of patients with irregular astigmatism after corneal transplantation by analyzing ocular parameters and ocular surface conditions of patients after corneal transplantation.

NCT ID: NCT06013436 Completed - Dry Eye Clinical Trials

AST Combined With 0.05% Cyclosporin Eye Drop Improve Corneal Nerve Density in Patients With SS Dry Eye

AST/SS
Start date: June 1, 2022
Phase:
Study type: Observational

The objective of the present study was to evaluate the efficacy of autologous serum tears combined with 0.05% cyclosporin eye drop in treating Sjögren's syndrome dry eye and their effect on corneal nerves. We assessed the impact of 12-week AST combined with 0.05% cyclosporin eye drop treatment on signs, symptoms, and sub-basal nerve density (SND) in patients with dry eyes related to Sjogren's syndrome.

NCT ID: NCT05938985 Active, not recruiting - Dry Eye Clinical Trials

Croatian Version of the Ocular Surface Disease Index Questionnaire (OSDI)

Cro-OSDI
Start date: June 12, 2023
Phase:
Study type: Observational

Ocular Surface Disease Index (OSDI) Questionnaire is an important tool for the diagnosis of dry eye disease. Croatian version is yet not available. With a permission of AbbVie company investigators want to make a Croatian version of the Ocular Surface Disease Index Questionnaire (Cro-OSDI).

NCT ID: NCT05832996 Completed - Clinical trials for Ocular Surface Disease

Cool vs Room-temperature Artificial Tears

Start date: March 1, 2022
Phase: Phase 4
Study type: Interventional

Background and Objective: To evaluate the efficacy of cooled versus room temperature artificial tears in reducing post intravitreal injection (IVI) ocular discomfort. Patients and Methods: Patients receiving IVI were randomized to either cooled or room temperature tears intervention groups. Both groups rated their ocular discomfort following IVI before intervention and again after administration of cooled or room temperature tears.